Wakamoto Pharmaceutical Co., Ltd.(JP:4512)
Â¥286.00-1.00 (-0.35%)
JP:4512
Wakamoto Pharmaceutical Co., Ltd. financials statements
Â¥286.00
At close:-1.00 (-0.35%)
Want to see JP:4512 full AI Analyst Report?
Wakamoto Pharmaceutical Co., Ltd. (4512) Ratios
0 Followers
Wakamoto Pharmaceutical Co., Ltd. Ratios
JP:4512's free cash flow for Q3 2023 was ¥0.00. For the 2023 fiscal year, JP:4512's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.48 | 4.38 | 4.96 | 4.18 | 4.29 |
| Quick Ratio | 2.07 | 2.88 | 3.85 | 3.31 | 3.16 |
| Cash Ratio | 0.72 | 1.45 | 2.03 | 1.73 | 1.61 |
| Solvency Ratio | 0.15 | 0.15 | 0.13 | 0.13 | 0.20 |
| Operating Cash Flow Ratio | -0.18 | -0.29 | -0.06 | 0.28 | 0.17 |
| Short-Term Operating Cash Flow Coverage | -3.52 | -5.92 | -0.82 | 4.64 | 2.68 |
| Net Current Asset Value | ¥ 5.18B | ¥ 5.52B | ¥ 5.57B | ¥ 5.55B | ¥ 5.14B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.37 | 1.29 | 1.28 | 1.32 | 1.30 |
| Debt Service Coverage Ratio | 4.79 | 4.91 | 3.48 | 3.67 | 5.58 |
| Interest Coverage Ratio | 134.85 | -519.04 | -368.19 | 244.75 | -23.28 |
| Debt to Market Cap | 0.03 | 0.01 | 0.02 | 0.02 | 0.01 |
| Interest Debt Per Share | 11.58 | 2.91 | 3.78 | 3.99 | 3.74 |
| Net Debt to EBITDA | -2.29 | -6.51 | -7.00 | -6.50 | -4.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 47.75% | 46.50% | 45.76% | 47.44% | 51.96% |
| EBIT Margin | 2.61% | 0.11% | 2.06% | 2.45% | 3.40% |
| EBITDA Margin | 7.08% | 5.63% | 6.52% | 6.65% | 9.01% |
| Operating Profit Margin | 2.58% | -5.88% | -2.53% | 1.63% | -0.16% |
| Pretax Profit Margin | 2.59% | 0.10% | 2.05% | 2.44% | 3.40% |
| Net Profit Margin | 2.29% | 0.83% | 1.41% | 1.60% | 2.85% |
| Continuous Operations Profit Margin | 2.29% | 0.83% | 1.41% | 1.60% | 2.85% |
| Net Income Per EBT | 88.62% | 864.27% | 68.59% | 65.35% | 83.74% |
| EBT Per EBIT | 100.33% | -1.63% | -81.25% | 149.56% | -2128.03% |
| Return on Assets (ROA) | 1.38% | 0.43% | 0.71% | 0.88% | 1.60% |
| Return on Equity (ROE) | 1.89% | 0.56% | 0.91% | 1.16% | 2.08% |
| Return on Capital Employed (ROCE) | 1.86% | -3.53% | -1.44% | 1.05% | -0.10% |
| Return on Invested Capital (ROIC) | 1.63% | -3.50% | -0.98% | 0.68% | -0.09% |
| Return on Tangible Assets | 1.40% | 0.44% | 0.72% | 0.89% | 1.62% |
| Earnings Yield | 1.87% | 0.59% | 1.36% | 1.61% | 2.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.81 | 2.97 | 2.69 | 2.69 | 2.98 |
| Payables Turnover | 5.15 | 4.43 | 4.75 | 4.37 | 3.63 |
| Inventory Turnover | 1.32 | 1.37 | 2.09 | 2.33 | 1.79 |
| Fixed Asset Turnover | 2.71 | 2.35 | 2.56 | 2.86 | 2.54 |
| Asset Turnover | 0.60 | 0.52 | 0.50 | 0.55 | 0.56 |
| Working Capital Turnover Ratio | 1.44 | 1.11 | 1.08 | 1.26 | 1.34 |
| Cash Conversion Cycle | 335.40 | 307.77 | 233.13 | 208.53 | 225.94 |
| Days of Sales Outstanding | 129.76 | 123.08 | 135.59 | 135.46 | 122.40 |
| Days of Inventory Outstanding | 276.53 | 267.10 | 174.43 | 156.58 | 204.01 |
| Days of Payables Outstanding | 70.90 | 82.40 | 76.89 | 83.51 | 100.47 |
| Operating Cycle | 406.29 | 390.17 | 310.02 | 292.04 | 326.41 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -14.03 | -17.07 | -3.09 | 18.21 | 9.77 |
| Free Cash Flow Per Share | -30.30 | -30.04 | -19.10 | 12.12 | -0.83 |
| Dividend Paid and CapEx Coverage Ratio | -0.73 | -1.07 | -0.16 | 2.99 | 0.92 |
| Capital Expenditure Coverage Ratio | -0.86 | -1.32 | -0.19 | 2.99 | 0.92 |
| Operating Cash Flow Coverage Ratio | -1.22 | -5.92 | -0.82 | 4.59 | 2.63 |
| Operating Cash Flow to Sales Ratio | -0.05 | -0.08 | -0.01 | 0.07 | 0.04 |
| Free Cash Flow Yield | -8.63% | -9.48% | -8.27% | 4.91% | -0.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 53.59 | 170.43 | 73.58 | 62.01 | 42.05 |
| Price-to-Sales (P/S) Ratio | 1.23 | 1.41 | 1.04 | 0.99 | 1.20 |
| Price-to-Book (P/B) Ratio | 1.01 | 0.95 | 0.67 | 0.72 | 0.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.59 | -10.55 | -12.09 | 20.37 | -346.27 |
| Price-to-Operating Cash Flow Ratio | -25.02 | -18.57 | -74.69 | 13.57 | 29.57 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | -4.18 | -3.49 | -1.47 | -0.30 |
| Enterprise Value Multiple | 15.08 | 18.57 | 8.88 | 8.39 | 9.17 |
| Enterprise Value | 10.58B | 8.15B | 4.48B | 4.83B | 6.93B |
| EV to EBITDA | 15.08 | 18.57 | 8.88 | 8.39 | 9.17 |
| EV to Sales | 1.07 | 1.05 | 0.58 | 0.56 | 0.83 |
| EV to Free Cash Flow | -10.06 | -7.81 | -6.76 | 11.48 | -239.15 |
| EV to Operating Cash Flow | -21.72 | -13.75 | -41.77 | 7.65 | 20.42 |
| Tangible Book Value Per Share | 339.05 | 326.53 | 336.22 | 337.24 | 325.14 |
| Shareholders’ Equity Per Share | 346.01 | 334.53 | 346.51 | 343.06 | 330.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | -7.64 | 0.31 | 0.35 | 0.16 |
| Revenue Per Share | 285.45 | 224.44 | 222.97 | 249.53 | 241.54 |
| Net Income Per Share | 6.55 | 1.86 | 3.14 | 3.98 | 6.87 |
| Tax Burden | 0.89 | 8.64 | 0.69 | 0.65 | 0.84 |
| Interest Burden | 0.99 | 0.89 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.05 | 0.07 | 0.07 | 0.07 |
| SG&A to Revenue | 0.45 | 0.52 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -2.14 | -9.19 | -0.68 | 2.99 | 1.19 |
Currency in JPY
